After Jardiance Heart Failure Successes, BI And Lilly Focus On Kidney
Phase III Stopped Early
Jardiance, the best-selling SGLT2 inhibitor, has AstraZeneca’s same-class rival Farxiga firmly in its sights in renal disease after showing such a level of efficacy that the 6,600-patient EMPA-KIDNEY study has been halted.
